Enovis™ Announces Leadership Change to International Surgical Business
Enovis (NYSE: ENOV) has announced a leadership transition in its International Surgical Business. Davide Visentin will succeed Dr. Benjamin Reinmann as President, effective March 1, 2025. Visentin brings over 20 years of healthcare experience, most recently serving as VP and General Manager at BD's Integrated Diagnostic Solutions, where he managed 700+ employees across 50 countries.
Prior to BD, Visentin held leadership positions at Stryker's Joint Replacement and Robotic Division and Johnson & Johnson Depuy Synthes. He holds a Computer Science degree from the University of Milan and will primarily operate from Villanova, Italy, and Bettlach, Switzerland.
The company highlighted its progress in building its International Surgical Business, emphasizing its commitment to market share growth and innovation in global orthopedics.
Enovis (NYSE: ENOV) ha annunciato un cambiamento nella leadership della sua Business Internazionale di Chirurgia. Davide Visentin succederà al Dr. Benjamin Reinmann come Presidente, con effetto dal 1° marzo 2025. Visentin porta con sé oltre 20 anni di esperienza nel settore della salute, avendo recentemente ricoperto il ruolo di VP e Direttore Generale presso le Soluzioni Diagnostiche integrate di BD, dove ha gestito più di 700 dipendenti in 50 paesi.
Prima di entrare in BD, Visentin ha ricoperto posizioni dirigenziali nella Divisione Artroplastica e Robotica di Stryker e in Johnson & Johnson Depuy Synthes. Ha una laurea in Informatica conseguita presso l'Università di Milano e opererà principalmente da Villanova, in Italia, e Bettlach, in Svizzera.
L'azienda ha messo in evidenza i suoi progressi nella costruzione della sua Business Internazionale di Chirurgia, sottolineando il suo impegno per la crescita della quota di mercato e l'innovazione nell'ortopedia globale.
Enovis (NYSE: ENOV) ha anunciado una transición en el liderazgo de su Negocio Quirúrgico Internacional. Davide Visentin sucederá al Dr. Benjamin Reinmann como Presidente, a partir del 1 de marzo de 2025. Visentin aporta más de 20 años de experiencia en el sector de la salud, habiendo sido recientemente VP y Gerente General en las Soluciones de Diagnóstico Integradas de BD, donde gestionó a más de 700 empleados en 50 países.
Antes de BD, Visentin ocupó cargos de liderazgo en la División de Reemplazo Articular y Robótica de Stryker, así como en Johnson & Johnson Depuy Synthes. Posee un título en Ciencias de la Computación de la Universidad de Milán y operará principalmente desde Villanova, Italia, y Bettlach, Suiza.
La empresa destacó su progreso en la construcción de su Negocio Quirúrgico Internacional, enfatizando su compromiso con el crecimiento de la cuota de mercado y la innovación en ortopedia global.
Enovis (NYSE: ENOV)는 국제 외과 사업부의 리더십 전환을 발표했습니다. 다비드 비센틴이 2025년 3월 1일부터 벤자민 라인만 박사의 후임으로 사장직을 맡게 됩니다. 비센틴은 20년 이상의 의료 경험을 보유하고 있으며, 최근에는 BD의 통합 진단 솔루션에서 부사장 및 총괄 관리자로 근무하며 50개국에서 700명 이상의 직원을 관리했습니다.
BD 이전에 비센틴은 Stryker의 관절 교체 및 로봇 부문, 그리고 Johnson & Johnson Depuy Synthes에서 리더십 직책을 맡았습니다. 그는 밀라노 대학교에서 컴퓨터 과학 학위를 취득했으며, 주로 이탈리아의 빌라노바와 스위스의 베틀락에서 활동할 것입니다.
회사는 국제 외과 사업부의 발전을 강조하며, 시장 점유율 성장과 글로벌 정형외과 혁신에 대한 헌신을 강조했습니다.
Enovis (NYSE: ENOV) a annoncé une transition de leadership dans son entreprise internationale de chirurgie. Davide Visentin succédera au Dr Benjamin Reinmann en tant que président, à compter du 1er mars 2025. Visentin apporte plus de 20 ans d'expérience dans le secteur de la santé, ayant récemment été VP et directeur général chez BD's Integrated Diagnostic Solutions, où il a géré plus de 700 employés dans 50 pays.
Avant BD, Visentin a occupé des postes de direction dans la division de remplacement articulaire et robotique de Stryker ainsi qu'à Johnson & Johnson Depuy Synthes. Il est titulaire d'un diplôme en informatique de l'Université de Milan et travaillera principalement à partir de Villanova, en Italie, et de Bettlach, en Suisse.
L'entreprise a souligné ses progrès dans la construction de son entreprise internationale de chirurgie, en mettant l'accent sur son engagement envers la croissance de sa part de marché et l'innovation en orthopédie mondiale.
Enovis (NYSE: ENOV) hat einen Übergang in der Führung ihres Internationalen Chirurgiegeschäfts angekündigt. Davide Visentin wird Dr. Benjamin Reinmann als Präsident ab dem 1. März 2025 nachfolgen. Visentin bringt über 20 Jahre Erfahrung im Gesundheitswesen mit, zuletzt als VP und General Manager bei BD's Integrated Diagnostic Solutions, wo er über 700 Mitarbeiter in 50 Ländern leitete.
Vor BD hatte Visentin Führungspositionen in der Gelenkersatz- und Robotikabteilung von Stryker sowie bei Johnson & Johnson Depuy Synthes inne. Er hat einen Abschluss in Informatik von der Universität Mailand und wird hauptsächlich von Villanova, Italien, und Bettlach, Schweiz, aus arbeiten.
Das Unternehmen hob seine Fortschritte im Aufbau seines Internationalen Chirurgiegeschäfts hervor und betonte sein Engagement für das Wachstum des Marktanteils und Innovationen in der globalen Orthopädie.
- Appointment of an experienced executive with proven track record in healthcare and orthopedics
- New leader brings extensive international management experience (700+ employees, 50 countries)
- Strategic continuity in key markets (Italy and Switzerland operations)
- None.
Wilmington, DE, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Enovis™, a global medical technology innovator headquartered in the United States, announced recently that Davide Visentin will succeed Dr. Benjamin Reinmann as President of Enovis International Surgical, effective March 1, 2025.
Visentin is a successful MedTech executive who comes to Enovis with more than 20 years of healthcare experience. Most recently, he was the Vice President and General Manager of the Integrated Diagnostic Solutions Business Unit for BD, where he managed more than 700 employees across 50 countries and gained market share in a very competitive market. Prior to BD, Visentin served as Vice President and General Manager of Europe for Stryker’s Joint Replacement and Robotic Division, and Vice President, EMEA, for Johnson & Johnson Depuy Synthes.
“Under Benjamin Reinmann’s leadership, Enovis has created a world-class International Surgical Business. We sincerely thank Benjamin for his numerous contributions to the growth and success of both Enovis and Mathys, and especially throughout the critical integration of legacy companies Mathys and LimaCorporate,” said Louie Vogt, Group President of Enovis’ Reconstructive Business Group. “We are very excited to welcome Davide to Enovis. He is a dynamic leader with a strong track record of successfully growing businesses, a true passion for orthopedics, and the experience and playbook to take our business to the next level.”
Visentin has a degree in Computer Science from the University of Milan. He will primarily spend his time in Villanova, Italy, and Bettlach, Switzerland.
“We continue to make great progress with building and growing our International Surgical Business into a global orthopedics leader that is thriving because of our team’s commitment to excellence and to going above and beyond every day to create better together,” added Vogt. “The momentum we created in 2024 puts us in a strong position to advance our strategic goals, continue gaining market share and drive growth through innovation, all with the ultimate goal of improving patient outcomes.”
About Enovis
Enovis™ (NYSE: ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solutions that enhance patient outcomes and restore motion for life. We partner with the brightest minds in health to advance care that is smarter, personalized, and more effective, while improving operational efficiency for surgeons and clinicians around the world. Enovis solutions impact the well-being of millions of patients wherever they are on their pathway to health. Learn more about Enovis at www.enovis.com.
Media Contact
Lee Griffin
Vice President, Global Marketing Communications & Digital, Enovis
+1 (469) 794-9760
Lee.Griffin@enovis.com
FAQ
When will Davide Visentin start as President of Enovis International Surgical?
What is Davide Visentin's previous experience before joining ENOV?
Where will Davide Visentin be based for his role at ENOV?
Who did Davide Visentin replace as President of Enovis International Surgical?
What was the scope of Visentin's responsibility at his previous role?
